Agonox, Inc

AgonOx, Inc. develops novel therapies to treat cancer patients. The research strategy at AgonOx focuses on the interaction between T cells and tumor cells. Using bioinformatics, in-vitro, and in-vivo testing to identify and validate new therapeutic approaches. AgonOx conducts its research in laboratories at the Portland Providence Cancer Center where staff scientists work closely with oncologists, surgeons, and immunologists. This collaboration has led to two first-in-human clinical trials with the latest commencing in August 2023. The company’s focus in recent years has been utilizing selected tumor-reactive T cells in adoptive cell therapy for the treatment of patients with solid malignancies.